Nutrition, Metabolism & Cardiovascular Diseases
Volume 17, Issue 9 , Pages 657-665 , November 2007

Use of margarine enriched in phytosterols by patients at high cardiovascular risk and treated by hypolipidemic drugs

  • Laurent Laforest

      Affiliations

    • Université de Lyon, Lyon, F-69003, Lyon 1 University, Pharmacoepidemiology, EA3091, France
    • ,
  • Philippe Moulin

      Affiliations

    • Endocrinology, CHU-Lyon, France
    • ,
  • Marie-Sophie Schwalm

      Affiliations

    • Thalès Database, Boulogne Billancourt, France
    • ,
  • Philippe Le Jeunne

      Affiliations

    • Thalès Database, Boulogne Billancourt, France
    • ,
  • Stephanie Chretin

      Affiliations

    • Université de Lyon, Lyon, F-69003, Lyon 1 University, Pharmacoepidemiology, EA3091, France
    • ,
  • Brice Kitio

      Affiliations

    • Université de Lyon, Lyon, F-69003, Lyon 1 University, Pharmacoepidemiology, EA3091, France
    • ,
  • Jacques Massol

      Affiliations

    • Therapeutics, CHU-Besancon, France
    • ,
  • Eric Van Ganse

      Affiliations

    • Université de Lyon, Lyon, F-69003, Lyon 1 University, Pharmacoepidemiology, EA3091, France
    • Corresponding Author InformationCorresponding author. Unité de Pharmacoépidémiologie, EA3091, Lyon-Sud, 165 chemin du Grand Revoyet, BP 12, F-69921 Oullins Cedex, France. Tel.: +33 426 23 59 82; fax: +33 426 23 59 86.

Received 24 April 2006 ,Revised 25 July 2006 ,Accepted 26 July 2006.

References 

  1. Sacks FM, Pfeffer MA, Moyle LA, Rouleau JL, Rutherford JD, Cole TG, et al. For the Cholesterol and Recurrent Events Trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001–1009
  2. The long-term intervention with pravastatin in ischemic disease (LIPID) study group . Prevention of cardiovascular events and deaths with pravastatin in patients with coronary heart disease and broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349–1357
  3. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301–1307
  4. Heart Protection Study Group . MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled group. Lancet. 2002;360:7–22
  5. Muls E, Van Ganse E, Closing MC. Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk model. Atherosclerosis. 1998;137:S111–S116
  6. Mihaylova B, Briggs A, Armitage J, Parish S, Gray A, Collins R Heart Protection Study Collaborative Group. Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals. Lancet. 2005;365:1779–1785
  7. French Health Products Safety Agency [Agence Française de Sécurité Sanitaire des Produits de Santé]. Therapeutic management of dyslipidemic patient – September 2000.
  8. Van Ganse E, Souchet T, Laforest L, Moulin P, Bertrand M, Le Jeunne P, et al. Ineffectiveness of lipid-lowering therapy in primary care. Br J Clin Pharmacol. 2005;59:456–463
  9. Van Ganse E, Souchet T, Laforest L, Moulin P, Bertrand M, Le Jeunne P, et al. Long-term achievement of the therapeutic objectives of lipid-lowering agents in primary prevention patients and cardiovascular outcomes: an observational study. Atherosclerosis. 2005 Jul;19:
  10. Law M. Plant sterol and stanol margarines and health. BMJ. 2000;320:861–864
  11. Maki KC, Davidson MH, Umporowicz DM, Schaefer EJ, Dicklin MR, Ingram KA, et al. Lipid responses to plant-sterol-enriched reduced-fat spreads incorporated into a National Cholesterol Education Program Step I diet. Am J Clin Nutr. 2001 Jul;74(1):33–43
  12. Kozlowska-Wojciechowska M, Jastrzebska M, Naruszewicz M, Foltynska A. Impact of margarine enriched with plant sterols on blood lipids, platelet function, and fibrinogen level in young men. Metabolism. 2003;52:1373–1378
  13. Moghadasian MH, McManus BM, Pritchard PH, Frohlich JJ. “Tail oil”-derived phytosterols reduce atherosclerosis in apoE-deficient mice. Arterioscler Thromb Vasc Biol. 1997;17:119–126
  14. de Jong A, Plat J, Mensink RP. Metabolic effects of plant sterols and stanols (review). J Nutr Biochem. 2003;14:362–369
  15. Patch CS, Tapsell LC, Williams PG. Plant sterol/stanol prescription is an effective treatment strategy for managing hypercholesterolemia in outpatient clinical practice. J Am Diet Assoc. 2005;105:46–52
  16. Simons LA. Additive effect of plant sterol-ester margarine and cerivastatin in lowering low-density lipoprotein cholesterol in primary hypocholesterolemia. Am J Cardiol. 2002;90:737–740
  17. Wang JS, Carson EC, Lapane KL, Eaton CB, Gans KM, Lasater TM. The effect of physician office visits on CHD risk factor modification as part of a worksite cholesterol screening program. Prev Med. 1999;28:221–228
  18. Oliver-Mcneil S, Artinian NT. Women's perceptions of personal cardiovascular risk and their risk-reducing behaviors. Am J Crit Care. 2002;11:221–227
  19. Ferrario G, Alkhimovitch O, Avanzini F, Cirrincione C, Galloni G, Marchesi S, et al. People's perception of their overall coronary risk: an Italian experience. Ital Heart J. 2004;5:16–21
  20. Hobbs FD, Erhardt L. Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the Reassessing European Attitudes about Cardiovascular Treatment (REACT) survey. Fam Pract. 2002;19:596–604
  21. McBride P, Schrott HG, Plane MB, Underbakke G, Brown RL. Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease. Arch Intern Med. 1998;158:1238–1244
  22. Backlund L, Bring J, Strender L-E. How accurately do general practitioners and students estimate coronary risk in hypercholesterolaemic patients?. Prim Health Care Res Dev. 2004;5:145–152
  23. De Muylder R, Lorant V, Paulus D, Nackers F, Jeanjean M, Boland B. Obstacles to cardiovascular prevention in general practice. Acta Cardiol. 2004;59:119–125
  24. Consoli SM, Bruckert E. Educational level has a major impact on the representations of cholesterol: a study in 1579 hypercholesterolemic patients. Prev Med. 2004;38:323–329
  25. Reddy E, Kreher N, Hickner JM. How concerned are elderly patients without coronary heart disease about hypercholesterolemia and heart disease? An UPRNet study. Upper Peninsula Research Network. J Fam Pract. 1998;46:227–232
  26. Shimakawa T, Sorlie P, Carpenter MA, Dennis B, Tell GS, Watson R, et al. Dietary intake patterns and sociodemographic factors in the atherosclerosis risk in communities study. ARIC Study Investigators. Prev Med. 1994;23:769–780

PII: S0939-4753(06)00168-2

doi: 10.1016/j.numecd.2006.07.012

Nutrition, Metabolism & Cardiovascular Diseases
Volume 17, Issue 9 , Pages 657-665 , November 2007

Article Tools